Author: Vaxcyte, Inc.

Posted Date:

May 8, 2026

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Vaxcyte, Inc.

May 8, 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Vaxcyte, Inc.

April 7, 2026
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte, Inc.

March 23, 2026
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Vaxcyte, Inc.

March 18, 2026
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vaxcyte, Inc.

February 25, 2026
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Vaxcyte, Inc.

February 12, 2026
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

Vaxcyte, Inc.

February 10, 2026
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

Vaxcyte, Inc.

February 7, 2026
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Vaxcyte, Inc.

February 2, 2026
Vaxcyte Announces Pricing of $550 Million Public Offering

Vaxcyte, Inc.

January 30, 2026